Robert Driscoll
Stock Analyst at Wedbush
(3.26)
# 1,032
Out of 5,245 analysts
179
Total ratings
39.62%
Success rate
4.4%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Robert Driscoll
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TNGX Tango Therapeutics | Maintains: Outperform | $19 → $33 | $20.24 | +63.04% | 6 | May 14, 2026 | |
| APRE Aprea Therapeutics | Maintains: Outperform | $7 → $6 | $0.95 | +531.58% | 6 | May 14, 2026 | |
| AVTX Avalo Therapeutics | Maintains: Outperform | $40 → $34 | $16.35 | +107.95% | 2 | May 14, 2026 | |
| EIKN Eikon Therapeutics | Maintains: Underperform | $7 → $5 | $10.91 | -54.17% | 3 | May 12, 2026 | |
| JANX Janux Therapeutics | Maintains: Outperform | $45 → $36 | $14.52 | +147.93% | 8 | May 8, 2026 | |
| CGEM Cullinan Therapeutics | Maintains: Outperform | $36 → $37 | $13.84 | +167.34% | 7 | May 8, 2026 | |
| RVMD Revolution Medicines | Maintains: Outperform | $147 → $165 | $151.56 | +8.87% | 11 | May 7, 2026 | |
| PYXS Pyxis Oncology | Initiates: Outperform | $6 | $1.96 | +206.12% | 1 | May 5, 2026 | |
| IDYA IDEAYA Biosciences | Maintains: Outperform | $52 → $58 | $29.10 | +99.31% | 12 | Apr 14, 2026 | |
| REPL Replimune Group | Downgrades: Neutral | $19 → $2 | $4.91 | -59.27% | 9 | Apr 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $37 → $41 | $23.43 | +74.99% | 8 | Apr 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $13 → $14 | $2.28 | +514.04% | 11 | Mar 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $11 | $3.76 | +192.55% | 10 | Mar 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $10 | $4.22 | +136.97% | 8 | Mar 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $38 → $36 | $11.25 | +220.00% | 12 | Mar 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $9 → $11 | $9.09 | +21.01% | 10 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $37 → $53 | $32.47 | +63.23% | 10 | Feb 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $70 | $64.13 | +9.15% | 1 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $38 | $11.35 | +234.80% | 2 | Oct 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $27 | $20.74 | +30.18% | 1 | Jul 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $4 | $4.06 | -1.48% | 11 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $6 | $0.4436 | +1,252.57% | 3 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $17 | $18.81 | -9.62% | 4 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $80 | $8.30 | +863.86% | 8 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $8 | $2.07 | +286.47% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $7 | $1.28 | +446.88% | 8 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $2 → $4 | $4.35 | -8.05% | 4 | May 19, 2020 |
Tango Therapeutics
May 14, 2026
Maintains: Outperform
Price Target: $19 → $33
Current: $20.24
Upside: +63.04%
Aprea Therapeutics
May 14, 2026
Maintains: Outperform
Price Target: $7 → $6
Current: $0.95
Upside: +531.58%
Avalo Therapeutics
May 14, 2026
Maintains: Outperform
Price Target: $40 → $34
Current: $16.35
Upside: +107.95%
Eikon Therapeutics
May 12, 2026
Maintains: Underperform
Price Target: $7 → $5
Current: $10.91
Upside: -54.17%
Janux Therapeutics
May 8, 2026
Maintains: Outperform
Price Target: $45 → $36
Current: $14.52
Upside: +147.93%
Cullinan Therapeutics
May 8, 2026
Maintains: Outperform
Price Target: $36 → $37
Current: $13.84
Upside: +167.34%
Revolution Medicines
May 7, 2026
Maintains: Outperform
Price Target: $147 → $165
Current: $151.56
Upside: +8.87%
Pyxis Oncology
May 5, 2026
Initiates: Outperform
Price Target: $6
Current: $1.96
Upside: +206.12%
IDEAYA Biosciences
Apr 14, 2026
Maintains: Outperform
Price Target: $52 → $58
Current: $29.10
Upside: +99.31%
Replimune Group
Apr 13, 2026
Downgrades: Neutral
Price Target: $19 → $2
Current: $4.91
Upside: -59.27%
Apr 2, 2026
Maintains: Outperform
Price Target: $37 → $41
Current: $23.43
Upside: +74.99%
Mar 17, 2026
Maintains: Outperform
Price Target: $13 → $14
Current: $2.28
Upside: +514.04%
Mar 17, 2026
Maintains: Outperform
Price Target: $6 → $11
Current: $3.76
Upside: +192.55%
Mar 12, 2026
Reiterates: Outperform
Price Target: $10
Current: $4.22
Upside: +136.97%
Mar 6, 2026
Maintains: Outperform
Price Target: $38 → $36
Current: $11.25
Upside: +220.00%
Feb 25, 2026
Maintains: Neutral
Price Target: $9 → $11
Current: $9.09
Upside: +21.01%
Feb 13, 2026
Maintains: Outperform
Price Target: $37 → $53
Current: $32.47
Upside: +63.23%
Dec 11, 2025
Initiates: Outperform
Price Target: $70
Current: $64.13
Upside: +9.15%
Oct 20, 2025
Maintains: Outperform
Price Target: $31 → $38
Current: $11.35
Upside: +234.80%
Jul 14, 2025
Initiates: Outperform
Price Target: $27
Current: $20.74
Upside: +30.18%
May 15, 2025
Reiterates: Neutral
Price Target: $4
Current: $4.06
Upside: -1.48%
May 9, 2025
Maintains: Outperform
Price Target: $8 → $6
Current: $0.4436
Upside: +1,252.57%
Mar 21, 2025
Maintains: Outperform
Price Target: $15 → $17
Current: $18.81
Upside: -9.62%
Sep 20, 2024
Reiterates: Outperform
Price Target: $80
Current: $8.30
Upside: +863.86%
Aug 7, 2024
Reiterates: Outperform
Price Target: $8
Current: $2.07
Upside: +286.47%
Jun 7, 2024
Reiterates: Outperform
Price Target: $7
Current: $1.28
Upside: +446.88%
May 19, 2020
Upgrades: Outperform
Price Target: $2 → $4
Current: $4.35
Upside: -8.05%